Product Center
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-02-18
- Views:
(Summary description)Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully held
(Summary description)Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-02-18 11:39
- Views:
Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
Herpes zoster (HZ) is caused by the varicella-zoster virus (VZV). Primary infection with this virus initially leads to chickenpox, after which the virus migrates from skin lesions and becomes latent in cranial ganglia, dorsal root ganglia, and autonomic ganglia along the neural axis. As people age or when their body's resistance decreases due to certain stimuli, VZV can be reactivated and cause herpes zoster. The general population is susceptible to VZV. Serological evidence shows that the VZV infection rate in adults is as high as over 90%, so the population is generally likely to develop herpes zoster. Herpes zoster can occur at any age, but its incidence rises significantly with increasing age. Herpes zoster not only affects the physical and mental health of patients, leading to a decline in their quality of life, but also imposes a significant disease burden and public health problem on families and society.
Our company has independently developed a recombinant herpes zoster vaccine (CHO cells), which incorporates a patented gE protein sequence, retains the advantageous antigenic epitopes, and innovatively employs a dual adjuvant system. This vaccine can effectively stimulate a specific immune response against VZV. Pre-clinical study data demonstrate that this vaccine induces stronger cell-mediated immune responses in animal models, suggesting potentially enhanced immunogenicity. Additionally, its high expression level of antigenic proteins may help reduce industrial production costs. If successfully approved for market, this vaccine will significantly improve the current supply of herpes zoster vaccines, offering the public a cost-effective vaccination option while strengthening our company’s competitive edge in the vaccine sector.
Relevant information
-
The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. - Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
